Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Philips shares slump on profit warning and sleep apnea device writedown

Published 12/10/2022, 06:17
Updated 12/10/2022, 22:00
© Reuters. FILE PHOTO: Logo of Dutch technology company Philips is seen at its company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier

By Bart H. Meijer

AMSTERDAM (Reuters) -Philips shares fell to their lowest in a decade on Wednesday as the Dutch health tech company said supply chain problems would hit sales, and wrote down 1.3 billion euros ($1.26 billion) of the value of its sleep apnea business.

Shares were down 9% at 0750 GMT at 14.13 euros, hitting their lowest level since June 2012.

In its second profit warning of the year, Philips said third-quarter core profit would drop around 60%, as ongoing supply chain problems had pushed down comparable sales by around 5%.

Philips said problems with supply shortages had been much greater than anticipated in the past months, after some signs of improvement earlier in the year, and would continue to weigh on sales in the last months of 2022.

This was expected to have limited adjusted earnings before interest, taxes and amortisation (EBITA) to 210 million euros in the third quarter, down from 512 million euros a year before.

Philips also slashed its outlook for the fourth quarter, as it now expects a "mid-single-digit" comparable sales decline while it previously guided for improvement towards the end of the year.

"This weakness will also spill into 2023 where consensus on adjusted EBITA probably also needs to come down by at least 10%," ING analyst Marc Hesselink said in a note.

"Next step will be the 2025 targets which became very challenging especially now that the Sleep & Respiratory care business is not expected to fully recover post the recall."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

RECALL HITS SLEEP BUSINESS

Philips last year shocked investors by recalling 5.5 million ventilators used to treat sleep apnoea, over worries that foam used in the machines could become toxic.

Outgoing Chief Executive Frans van Houten said the impairment on the sleep care business was the "best estimate" of the effects of a consent decree proposed by the U.S. Food and Drug Administration to solve the problems, which have lopped around 28 billion euros off Philips' market value in the past 15 months.

"Details of the consent decree have not been fully negotiated at this time," Van Houten said in a call with analysts. "It's really early days, we can't give much more detail today."

Van Houten will hand over the reins of the company to newly elected CEO Roy Jakobs by the end of the week, after Philips in August had unexpectedly announced his departure.

Philips will publish its full third-quarter results on Oct. 24.

($1 = 1.0298 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.